BioSpace News Archive

InMode Ltd., a leading global provider of innovative medical technologies, is pleased to announce that the US Patent and Trademark Office has granted to InMode Patent No. 10.799.285 covering its Morphues8 full body fractional radiofrequency technology.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced that it will host a CD33 program update featuring two key opinion leaders (KOLs) today, November 11th at 4:15 PM ET

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), today announced its operational and financial results for the three and nine months ended September 30, 2020.

Halo Health’s latest release of the Halo Clinical Collaboration Platform (CCP), featuring Halo Link, empowers organizations to easily collaborate and communicate with clinicians in affiliated organizations and across health networks.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that a recent Company whitepaper demonstrates that the CoPrimer™ platform technology can be used to identify the presence of SARS-CoV-2 in human saliva samples without first requiring RNA extraction of the sample,

Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation for AB-205, for “the treatment of organ vascular niche injuries to prevent or reduce severe regimen-related toxicities (SRRT) in pa

Following an initial 12-week induction treatment phase, fewer patients treated with abrocitinib experienced a flare than those on placebo at any point in the trial over 40 weeks

G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will present a company update at the Stifel 2020 Virtual Healthcare conference on November 18, 2020 at 11:20 a.m. ET. To access the live and archived webcast of the presentation, please visit the Events & Pr e sentations page of the G1 we b site . About G1 Therapeutics G1 Therapeutics,

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will participate in the upcoming investor conferences in November

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, has been invited to present at three upcoming virtual investor conferences in November. Details are as follows: Event Virtual Fall Investor Summit Date November 16, 2020 Time 1:30 p.m. ET Event Sidoti Virtual Micro